CUV 2.01% $15.21 clinuvel pharmaceuticals limited

***why it will break new highs **, page-15

  1. 1,571 Posts.
    fyi This came from a poster on ozestock!

    Sun shines on tan pioneer - Herald Sun
    Edition 1 - FIRSTMON 15 NOV 2004, Page 034
    Sun shines on tan pioneer
    By CLIVE HENLEY


    Epitan (EPT)

    Epitan listed in early 2001 to commercialise Melanotan, the company's principal skin cancer prevention and tanning product.

    This pharmaceutical mimics the human body's own skin tanning hormone, alpha-Melanocyte Stimulating Hormone, or a-MSH. Epitan's product will give you a natural tan without exposure to damaging UV sunlight.
    The company has completed a number of successful clinical trials here in Australia and the US demonstrating safety, tanning and a reduction in sunburn injury.

    The maturity of the project has resulted in granted patents in all major countries with further patents in the pipeline. In September 2004, EPT listed on the Frankfurt Stock Exchange and is in the early stages of listing on the US Nasdaq.

    The company has started discussions with a number of pharmaceutical companies with a view to joint development. Once approved by the regulatory authorities, Epitan anticipates Melanotan's product release in 2006 /2007 engaging a significant annual global market. The company reports $10.7 million in cash reserves.

    Technical Comment: Our most recent review of Epitan was in October last year. The stock was then trading at around 75 and we were able to glean a target of around $1.10. In early 2004, the stock moved to $1.08 and then pulled back to below $1 for most of the current year. It has received speculative support at this level which is a feature of this stock which demonstrates likely buying support.

    On three occasions now these reaccumulation areas have provided a springboard for a subsequent advance.

    The technical picture continues to demonstrate a solid true upward trend which, together with the continual buying support on price declines, reinforces the likelihood of still higher prices to come.
    In fact, prices of around $1.50 can now be put in prospect as the recent price action reinforces earlier activity.

    Clive Henley is a technical analyst /adviser at Tolhurst Noall. email [email protected].
    Direct: 9242 4143.

    Caption: Epitan (EPT)
    Illus: Graph
    Section: MONEY
    Type: Analysis


 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$15.21
Change
0.300(2.01%)
Mkt cap ! $762.0M
Open High Low Value Volume
$14.92 $15.28 $14.92 $915.0K 60.34K

Buyers (Bids)

No. Vol. Price($)
1 6078 $15.10
 

Sellers (Offers)

Price($) Vol. No.
$15.24 2000 1
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
$15.20
  Change
0.300 ( 1.88 %)
Open High Low Volume
$14.98 $15.26 $14.98 9078
Last updated 15.59pm 10/05/2024 ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.